A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer

NCT03086369 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

184

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG: Olaratumab
DRUG: Nab-paclitaxel
DRUG: Gemcitabine
DRUG: Placebo

Sponsor

Eli Lilly and Company